2023-07-10 13:00:09 ET
Novartis ( NYSE: NVS ) said it has received expanded approval for its cholesterol-fighting drug Leqvio from US regulators.
The FDA has approved Leqvio, also known as inclisiran, for the treatment of high LDL cholesterol in adults who are at increased risk of developing heart disease but who have not experienced a cardiovascular event. The drug, which is injected twice a year after an initial two dose round, is to be used in conjunction with diet and statins to help control the condition.
Leqvio is already approved in the US to treat atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. The drug was first approved by the FDA in December 2021.
More on Novartis:
- Novartis drops amid loss in patent ruling related to Entresto drug (update)
- Generic drugs lobby sues Minnesota over price control law
- More AbbVie Humira biosimilars launched (updated)
For further details see:
Novartis gets expanded FDA approval for cholesterol drug Leqvio